NYSE:BMY

Bristol-Myers Squibb News Headlines

$62.61
+0.70 (+1.13 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$61.68
Now: $62.61
$62.64
50-Day Range
$59.34
MA: $61.84
$64.07
52-Week Range
$54.07
Now: $62.61
$67.16
Volume7.87 million shs
Average Volume12.62 million shs
Market Capitalization$139.87 billion
P/E RatioN/A
Dividend Yield3.17%
Beta0.67

Headlines

Bristol-Myers Squibb (NYSE BMY) News Headlines Today

SourceHeadline
Bristol-Myers Squibb (NYSE:BMY) Upgraded to Buy by Zacks Investment ResearchBristol-Myers Squibb (NYSE:BMY) Upgraded to Buy by Zacks Investment Research
marketbeat.com - April 6 at 10:16 AM
3 Health Care Stocks with Healthy Growth Trends (BMY)3 Health Care Stocks with Healthy Growth Trends (BMY)
marketbeat.com - November 25 at 10:22 AM
 Analysts Anticipate Bristol-Myers Squibb (NYSE:BMY) Will Announce Earnings of $1.81 Per Share Analysts Anticipate Bristol-Myers Squibb (NYSE:BMY) Will Announce Earnings of $1.81 Per Share
americanbankingnews.com - April 11 at 6:22 AM
BRIEF-Bristol-Myers Squibb Says Opdivo Plus Chemotherapy Significantly Improves Pathologic Complete Response In Patients With Resectable Non-Small Cell Lung Cancer In Phase 3 TrialBRIEF-Bristol-Myers Squibb Says Opdivo Plus Chemotherapy Significantly Improves Pathologic Complete Response In Patients With Resectable Non-Small Cell Lung Cancer In Phase 3 Trial
msn.com - April 10 at 10:39 AM
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 TrialNeoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
finance.yahoo.com - April 10 at 10:39 AM
Bristol Myers (BMY) Opdivo Combo Positive in ESCC StudyBristol Myers' (BMY) Opdivo Combo Positive in ESCC Study
finance.yahoo.com - April 9 at 5:34 PM
What Kind Of Investors Own Most Of Bristol-Myers Squibb Company (NYSE:BMY)?What Kind Of Investors Own Most Of Bristol-Myers Squibb Company (NYSE:BMY)?
nasdaq.com - April 9 at 4:32 PM
Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell CarcinomaBristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma
finance.yahoo.com - April 8 at 7:40 AM
PsiOxus Therapeutics-Bristol Myers Expand Immuno-Oncology CollaborationPsiOxus Therapeutics-Bristol Myers Expand Immuno-Oncology Collaboration
finance.yahoo.com - April 7 at 1:48 PM
PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology CollaborationPsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration
businesswire.com - April 7 at 8:48 AM
3 Reasons Why Bristol Myers (BMY) Is a Great Growth Stock3 Reasons Why Bristol Myers (BMY) Is a Great Growth Stock
finance.yahoo.com - April 6 at 6:09 PM
Is Bristol Myers Squibb (BMY) Outperforming Other Medical Stocks This Year?Is Bristol Myers Squibb (BMY) Outperforming Other Medical Stocks This Year?
finance.yahoo.com - April 6 at 1:09 PM
3 Reasons Warren Buffett Loves Bristol-Myers Squibb3 Reasons Warren Buffett Loves Bristol-Myers Squibb
seekingalpha.com - April 5 at 7:29 PM
IRS alleges Bristol-Myers Squibb owes more than $1B in taxes from offshore scheme - NYTIRS alleges Bristol-Myers Squibb owes more than $1B in taxes from offshore scheme - NYT
seekingalpha.com - April 3 at 8:07 AM
Bristol-Myers to pay $75 mln to settle claims of underpaying Medicaid rebatesBristol-Myers to pay $75 mln to settle claims of underpaying Medicaid rebates
reuters.com - April 1 at 11:31 PM
Bristol-Myers Squibb Company Stock Is Believed To Be Modestly UndervaluedBristol-Myers Squibb Company Stock Is Believed To Be Modestly Undervalued
finance.yahoo.com - April 1 at 11:31 PM
Bristol Myers In Over $1B Tax Brawl After Accidental Disclosure Of Offshore Patents Setup: NYTBristol Myers In Over $1B Tax Brawl After Accidental Disclosure Of Offshore Patents Setup: NYT
finance.yahoo.com - April 1 at 6:30 PM
An Accidental Disclosure Exposes a $1 Billion Tax Fight With Bristol MyersAn Accidental Disclosure Exposes a $1 Billion Tax Fight With Bristol Myers
nytimes.com - April 1 at 8:28 AM
The Fundamental Case for Bristol-myers Squibb $BMY Using a Price Based ModelThe Fundamental Case for Bristol-myers Squibb $BMY Using a Price Based Model
marketwatch.com - April 1 at 3:44 AM
bluebird (BLUE), Bristol Myers CAR T Cell Therapy Gets FDA Nodbluebird (BLUE), Bristol Myers CAR T Cell Therapy Gets FDA Nod
finance.yahoo.com - March 30 at 2:02 PM
Here’s Why Bristol Myers Squibb Stock Is Undervalued At $63Here’s Why Bristol Myers Squibb Stock Is Undervalued At $63
markets.businessinsider.com - March 30 at 10:44 AM
Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In MelanomaHuyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In Melanoma
finance.yahoo.com - March 30 at 8:30 AM
Ex-Dividend Reminder: Sysco Corp, Cardinal Health and Bristol Myers SquibbEx-Dividend Reminder: Sysco Corp, Cardinal Health and Bristol Myers Squibb
nasdaq.com - March 29 at 12:27 PM
Bluebird Shares Jump as FDA Approves Cancer TherapyBluebird Shares Jump as FDA Approves Cancer Therapy
finance.yahoo.com - March 29 at 9:58 AM
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial CarcinomaEuropean Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
finance.yahoo.com - March 29 at 7:27 AM
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple MyelomaU.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma
finance.yahoo.com - March 27 at 1:41 AM
U.S. FDA approves Bristol-Myers Squibbs multiple myeloma therapyU.S. FDA approves Bristol-Myers Squibb's multiple myeloma therapy
finance.yahoo.com - March 27 at 1:41 AM
Top lawyers pay at Philip Morris, PepsiCo and Bristol Myers Squibb disclosedTop lawyers' pay at Philip Morris, PepsiCo and Bristol Myers Squibb disclosed
reuters.com - March 26 at 8:40 PM
Bristol-Myers Squibb Company Stock Appears To Be Modestly UndervaluedBristol-Myers Squibb Company Stock Appears To Be Modestly Undervalued
finance.yahoo.com - March 26 at 3:39 PM
Why It Might Not Make Sense To Buy Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming DividendWhy It Might Not Make Sense To Buy Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming Dividend
ca.finance.yahoo.com - March 26 at 10:38 AM
Bristol Myers Squibb Announces Positive Results For Relativity-047 Study- Quick FactsBristol Myers Squibb Announces Positive Results For Relativity-047 Study- Quick Facts
markets.businessinsider.com - March 25 at 9:33 AM
Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary Endpoint of Progression-Free SurvivalBristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary Endpoint of Progression-Free Survival
finance.yahoo.com - March 25 at 9:33 AM
Bristol-myers Squibb Company (BMY) Chairman and CEO Giovanni Caforio Sold $1.6 million of SharesBristol-myers Squibb Company (BMY) Chairman and CEO Giovanni Caforio Sold $1.6 million of Shares
finance.yahoo.com - March 24 at 6:32 PM
Bristol-Myers Squibb (NYSE:BMY) CEO Giovanni Caforio Sells 25,000 SharesBristol-Myers Squibb (NYSE:BMY) CEO Giovanni Caforio Sells 25,000 Shares
americanbankingnews.com - March 24 at 5:14 PM
Cadila Healthcares subsidiary, Celgene Corporation of Bristol Myers Squibb settle patent litigationCadila Healthcare's subsidiary, Celgene Corporation of Bristol Myers Squibb settle patent litigation
in.finance.yahoo.com - March 24 at 3:42 AM
Regenerative Medicine Attracted Record $20 Billion in Funding in 2020Regenerative Medicine Attracted Record $20 Billion in Funding in 2020
finance.yahoo.com - March 23 at 3:21 PM
How to Develop Investment Plans for Bristol-myers Squibb $BMYHow to Develop Investment Plans for Bristol-myers Squibb $BMY
marketwatch.com - March 22 at 8:48 PM
Bristol Myers (BMY) NDA for Mavacamten Accepted by FDABristol Myers' (BMY) NDA for Mavacamten Accepted by FDA
finance.yahoo.com - March 22 at 10:46 AM
FDA Accepts New Drug Application For Bristol Myers Squibb’s MavacamtenFDA Accepts New Drug Application For Bristol Myers Squibb’s Mavacamten
finance.yahoo.com - March 22 at 10:46 AM
William Blair Comments on Bristol-Myers Squibbs Q4 2021 Earnings (NYSE:BMY)William Blair Comments on Bristol-Myers Squibb's Q4 2021 Earnings (NYSE:BMY)
americanbankingnews.com - March 22 at 2:02 AM
FDA Accepts Bristol-Myers Mavacamten Application In Inherited Heart Disease For ReviewFDA Accepts Bristol-Myers' Mavacamten Application In Inherited Heart Disease For Review
benzinga.com - March 19 at 1:02 PM
Why Idera Pharmaceuticals Shares Dropped 62% Lower TodayWhy Idera Pharmaceuticals Shares Dropped 62% Lower Today
feeds.benzinga.com - March 19 at 1:10 AM
BMY May 21st Options Begin TradingBMY May 21st Options Begin Trading
nasdaq.com - March 18 at 7:22 PM
4 Value Stocks Billionaires Cant Stop Buying4 Value Stocks Billionaires Can't Stop Buying
finance.yahoo.com - March 18 at 6:51 AM
AVEO Collaborates with Bristol Myers to Conduct Combo StudyAVEO Collaborates with Bristol Myers to Conduct Combo Study
nasdaq.com - March 15 at 6:49 PM
Fertility Services Market Analysis 2021 with Bristol-Myers Squibb, Coopersurgical, Abbott LaboratoriesFertility Services Market Analysis 2021 with Bristol-Myers Squibb, Coopersurgical, Abbott Laboratories
marketwatch.com - March 15 at 3:22 PM
Is Bristol Myers Squibb (BMY) Stock A Buy or Sell?Is Bristol Myers Squibb (BMY) Stock A Buy or Sell?
finance.yahoo.com - March 15 at 9:35 AM
How Stock Traders Daily uses Price Action in Bristol-myers Squibb $BMY to Define Opportunity and RiskHow Stock Traders Daily uses Price Action in Bristol-myers Squibb $BMY to Define Opportunity and Risk
marketwatch.com - March 13 at 8:07 AM
AVEO, Bristol Myers To Evaluate Fotivda - Opdivo In Phase 3 Trial In Relapsed Renal Cell CarcinomaAVEO, Bristol Myers To Evaluate Fotivda - Opdivo In Phase 3 Trial In Relapsed Renal Cell Carcinoma
markets.businessinsider.com - March 12 at 5:05 PM
Bristol-Myers Squibb Company (BMY) Presents at Barclays Global Healthcare Conference (Transcript)Bristol-Myers Squibb Company (BMY) Presents at Barclays Global Healthcare Conference (Transcript)
seekingalpha.com - March 11 at 7:24 AM
Bristol Myers Squibb to Report Results for First Quarter 2021 on April 29, 2021Bristol Myers Squibb to Report Results for First Quarter 2021 on April 29, 2021
finance.yahoo.com - March 11 at 7:24 AM
Looking at Bristol-Myers Again as the Quants Downgrade ItLooking at Bristol-Myers Again as the Quants Downgrade It
realmoney.thestreet.com - March 9 at 2:36 PM
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.